Zhang Peng, Lopez Rocio, Attaway Amy H, Georas Steve N, Khatri Sumita B, Abi-Saleh Simon, Zein Joe G
Respiratory Institute, Cleveland Clinic, Cleveland, Ohio.
Center for Populations Health Research, Cleveland Clinic, Cleveland, Ohio; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio.
J Allergy Clin Immunol Pract. 2021 Apr;9(4):1562-1569.e1. doi: 10.1016/j.jaip.2020.10.054. Epub 2020 Nov 9.
Asthma is a prevalent disease with a high economic cost. More than 50% of its direct cost relates to asthma hospitalizations. Diabetes mellitus (DM) is a significant comorbidity in asthmatic patients, yet its impact on asthma-related hospitalizations is unknown.
To compare the outcome of asthma-related hospitalizations in patients with and without DM.
Using Healthcare Cost and Utilization Project Nationwide Readmissions Database, we analyzed data of all adults with index admission for asthma and with no other chronic pulmonary conditions, and compared outcomes between patients with and without DM. Weighted regression analysis was used to determine the impact of DM on hospitalization outcomes. All multivariate regression models were adjusted for patient demographics, socioeconomic status, and chronic medical comorbidities.
A total of 717,200 asthmatic patients were included, with 202,489 (28.3%) having DM. Diabetic patients were older and had more comorbidities. When hospitalized for asthma, diabetic patients had increased hospital length of stay, cost, and risk for 30-day all-cause and asthma-related readmission. They also had a higher risk for developing nonrespiratory complications during their hospital stay compared with nondiabetic patients. The risk of mortality was similar between the 2 groups.
Patients hospitalized for asthma with coexisting DM had increased hospital length of stay, cost, and risk for readmission. Interventions are urgently needed to reduce the risk for hospital admission and readmission in patients with coexisting DM and asthma. These interventions would have profound economic and societal impact.
哮喘是一种常见疾病,经济成本高昂。其直接成本的50%以上与哮喘住院治疗有关。糖尿病(DM)是哮喘患者的一种重要合并症,但其对哮喘相关住院治疗的影响尚不清楚。
比较合并和未合并DM的患者哮喘相关住院治疗的结果。
利用医疗成本和利用项目全国再入院数据库,我们分析了所有因哮喘首次入院且无其他慢性肺部疾病的成年人的数据,并比较了合并和未合并DM的患者的结果。采用加权回归分析来确定DM对住院结果的影响。所有多变量回归模型均根据患者人口统计学、社会经济状况和慢性疾病合并症进行了调整。
共纳入717200例哮喘患者,其中202489例(28.3%)患有DM。糖尿病患者年龄较大,合并症较多。因哮喘住院时,糖尿病患者的住院时间、费用增加,30天全因再入院和哮喘相关再入院风险增加。与非糖尿病患者相比,他们在住院期间发生非呼吸并发症的风险也更高。两组之间的死亡率风险相似。
合并DM的哮喘住院患者的住院时间、费用和再入院风险增加。迫切需要采取干预措施来降低合并DM和哮喘患者的入院和再入院风险。这些干预措施将产生深远的经济和社会影响。